FLNA:BMV
Filana Therapeutics Inc
15,92 MX$
0,00%
(0,00) 1D
5 հոկ, 12:05:31 GMT-6 · MXN
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for FLNA...
Mkt. cap
34,02 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
56,00 MX$
52-wk low
15,92 MX$
No. of employees
19
Mkt. cap
34,02 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
56,00 MX$
52-wk low
15,92 MX$
No. of employees
19
News stories
From web sources and news partners
Simply Wall Street
·
29 րոպե առաջ
Freshworks (FRSH) Shares Just Moved, So What Is Going On?
KuCoin
·
19 րոպե առաջ
Nasdaq posts its worst weekly decline since June, gold rebounds but faces resistance at 4200
Yahoo Finance
·
14 ժամ առաջ
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
MarketWatch
·
1 օր առաջ
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profile
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to Cassava Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. Wikipedia
About Filana Therapeutics Inc